Sponsors
The bill narrows orphan-drug exclusivity to specific approved indications, which can speed competition, lower prices, and clarify rules for regulators but may reduce revenue incentives for developers, risking fewer rare-disease treatments and more legal disputes.
Patients with rare diseases or chronic conditions: gain faster access to alternative drugs for the same approved indication because orphan exclusivity is narrowed to specific approved uses.
Patients with affected indications: may see lower prices because narrowing exclusivity increases competition for specific indications.
Hospitals, health systems, manufacturers, and FDA: receive clearer regulatory standards because the bill defines 'approved use or indication,' reducing uncertainty about the scope of orphan exclusivity.
Small biotechnology firms and drug developers: could lose market protection for some indications, reducing expected revenue and potentially deterring investment in rare-disease R&D.
Patients with rare diseases or chronic conditions: may face fewer development programs and reduced future treatment options if investment in certain orphan-drug uses declines.
Hospitals, health systems, manufacturers, and patients: could face increased litigation or regulatory disputes over whether a competitor's drug shares the 'same approved use or indication,' raising compliance costs that may be passed to consumers.
Based on analysis of 2 sections of legislative text.
Limits orphan-drug exclusivity to the "same approved use or indication," defines that term, and applies the change regardless of designation or approval dates.
Amends the orphan-drug exclusivity test so exclusivity blocks only applications that seek approval for the exact same approved use or indication as the orphan drug, rather than for the broader “same disease or condition.” It also defines “approved use or indication” and makes the change apply to any designated or approved product regardless of dates, which can affect existing exclusivities.
Introduced January 28, 2026 by Tammy Baldwin · Last progress January 28, 2026